Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CDA | P32320 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15675815 | 1.00 | PDE4D (0.54) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL15717320 | 0.99 | PDE4D (0.55) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL13160995 | 0.99 | PDE4D (0.55) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL15675962 | 0.96 | PDE4D (0.56) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL19698969 | 0.96 | PDE4D (0.56) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL18759734 | 0.93 | PDE4D (0.46) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL13160999 | 0.90 | POLA1 (0.48) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL13161034 | 0.90 | POLA1 (0.48) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL13160971 | 0.89 | PDE4D (0.60) | PDE4DPDE3ASLC29A1LMNAPOLA1 | |
| SCHEMBL15675963 | 0.88 | PDE4D (0.57) | PDE4DPDE3ASLC29A1POLA1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020216646-A1 | CYTIDINE DERIVATIVES AND METHODS OF FORMING CYTIDINE DERIVATIVES | Aenorasis Commercial Company of Pharmaceutical and Medical Products and Machines Societe Anonyme (GR) | 2020-10-29 | — | — | WO | disclosed |
| US-9890189-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2018-02-13 | — | — | US | disclosed |
| US-9890189-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2018-02-13 | — | — | US | disclosed |
| US-9890189-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2018-02-13 | — | — | US | disclosed |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2017-04-20 | — | — | US | disclosed |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2017-04-20 | — | — | US | disclosed |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2017-04-20 | — | — | US | disclosed |
| US-9540410-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2017-01-10 | — | — | US | disclosed |
| US-9540410-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2017-01-10 | — | — | US | disclosed |
| US-9540410-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2017-01-10 | — | — | US | disclosed |
| US-20150132298-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2015-05-14 | — | — | US | disclosed |
| US-20150132298-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2015-05-14 | — | — | US | disclosed |
| US-20150132298-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2015-05-14 | — | — | US | disclosed |
| US-8956613-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2015-02-17 | — | — | US | disclosed |
| US-8956613-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2015-02-17 | — | — | US | disclosed |
| US-8956613-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2015-02-17 | — | — | US | disclosed |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-15 | — | — | US | disclosed |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-15 | — | — | US | disclosed |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150132298-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | CCNO, ABCB1, ABCC3 | PDE4D 3427/4885PDE3A 1346/4885SLC29A1 138/4885 |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | CCNO, ABCB1, ABCC3 | PDE4D 3427/4885PDE3A 1346/4885SLC29A1 138/4885 |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | CCNO, ABCB1, ABCC3 | PDE4D 3427/4885PDE3A 1346/4885SLC29A1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.